Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Semaglutide is a GLP-1 receptor agonist that mimics the action of the GLP-1 hormone
Some peptides can pose more specific dangers
Gastrointestinal symptoms, while frequent, typically improve within 48 weeks as the body adjusts to therapy
DPP-4 inhibitors have thereafter undergone long-term cardiovascular outcome trials, showing non-inferiority for risk of major acute cardiovascular endpoints
SOUL is the largest GLP-1 trial to include a prespecified secondary analysis of outcomes by concomitant sodium-glucose cotransporter-2 (SGLT2) inhibitor use, noted Nikolaus Marx, MD, Professor of Cardiology and Head of Internal Medicine, University Hospital Aachen, Germany
US$ 28.04
US$ 24.13
US$ 23.80
